Myeloid Leukemia News and Research RSS Feed - Myeloid Leukemia News and Research

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). [More]
Researchers find key mechanism that could lead to new effective treatments for leukemias

Researchers find key mechanism that could lead to new effective treatments for leukemias

Researchers have identified two proteins that appear crucial to the development -- and patient relapse -- of acute myeloid leukemia. They have also shown they can block the development of leukemia by targeting those proteins. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
BloodCenter of Wisconsin announces availability of cancer mutation HemeOnc Panel

BloodCenter of Wisconsin announces availability of cancer mutation HemeOnc Panel

BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a comprehensive cancer mutation HemeOnc Panel using next generation sequencing (NGS) technology. The NGS panel developed by BloodCenter of Wisconsin is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies. [More]
Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation (ODD) by the European Medicines Agency for the treatment of acute myeloid leukemia (AML). [More]
New standard of care for pediatric AML patients who receive umbilical cord transplants

New standard of care for pediatric AML patients who receive umbilical cord transplants

A new standard of care for children facing acute myeloid leukemia (AML) may be clear, following a multi-year study published in the latest edition of the New England Journal of Medicine. [More]
CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma Corp. today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited, the originator of tosedostat, and Chroma Therapeutics Ltd., through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America. [More]
Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies. [More]
Aptose joins Beat AML research collaboration

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs. [More]

Eutropics inks NCI contract to develop Praedicare Dx platform technology for AML treatments

EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment. [More]
Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). [More]
Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Virginia lawmakers will convene in a special session next month to address the question of expanding Medicaid and, more broadly, the fact that hundreds of thousands of poor and disabled people in the state have no health insurance coverage. Democrats and some moderate Republicans have advanced a variety of ideas to tackle that problem. Conservative Republicans, who control the legislature in Richmond, have rejected those solutions while proposing no alternative. Does the GOP intend for the special session to be anything more than a charade at taxpayers' expense? (8/15). [More]
Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease (IBD) patients. [More]
5-LO enzyme plays important role in the survival of leukaemic AML stem cells

5-LO enzyme plays important role in the survival of leukaemic AML stem cells

Despite improved therapy, only one out of every two adult patients survive acute myeloid leukaemia (AML). The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years. It is assumed that leukaemic stem cells, which cannot be completely eliminated during treatment, are the origin of relapse. [More]
FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. [More]
CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076. [More]